Suscribirse

Filaggrin breakdown products determine corneocyte conformation in patients with atopic dermatitis - 04/12/15

Doi : 10.1016/j.jaci.2015.04.042 
Christoph Riethmuller, PhD a, , Maeve A. McAleer, MRCP b, c, , Sjors A. Koppes, MD d, Rawad Abdayem, MSc e, Jonas Franz a, Marek Haftek, MD, PhD e, Linda E. Campbell, MSc f, Stephanie F. MacCallum, BSc f, W.H. Irwin McLean, PhD, DSc, FRS, FRSE, FMedSci f, Alan D. Irvine, MD b, c, f, g, , , Sanja Kezic, PhD d, ,
a Serend-ip GmbH, Munster, Germany 
b Department of Dermatology, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland 
c National Children's Research Centre, Our Lady's Children's Hospital, Crumlin, Dublin, Ireland 
d Coronel Institute of Occupational Health, Academic Medical Center, Amsterdam, The Netherlands 
e University of Lyon 1, EA4169 “Fundamental, clinical and therapeutic aspects of the skin barrier function”, Lyon, France 
f Centre for Dermatology and Genetic Medicine, Division of Molecular Medicine, Colleges of Life Sciences and Medicine, Dentistry & Nursing, University of Dundee, Dundee, United Kingdom 
g Clinical Medicine, Trinity College Dublin, Dublin, Ireland 

Corresponding author: Sanja Kezic, PhD, Coronel Institute of Occupational Health, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.Alan D. Irvine, MD, Pediatric Dermatology, Our Lady's Children's Hospital, Dublin.

Abstract

Background

Loss-of-function (LOF) mutations in the filaggrin gene (FLG) are a well-replicated risk factor for atopic dermatitis (AD) and are known to cause an epidermal barrier defect. The nature of this barrier defect is not fully understood. Patients with AD with FLG LOF mutations are known to have more persistent disease, more severe disease, and greater risk of food allergies and eczema herpeticum. Abnormalities in corneocyte morphology have been observed in patients with AD, including prominent villus-like projections (VP); however, these ultrastructural features have not been systematically studied in patients with AD in relation to FLG genotype and acute and convalescent status.

Objective

We sought to quantitatively explore the relationship between FLG genotype, filaggrin breakdown products (natural moisturizing factor [NMF]), and corneocyte morphology in patients with AD.

Methods

We studied 15 children at first presentation of AD and after 6 weeks of standard therapy. We applied atomic force microscopy to study corneocyte conformation in patients with AD stratified by FLG status and NMF level. By using a new quantitative methodology, the number of VPs per investigated corneocyte area was assessed and expressed as the Dermal Texture Index score. Corneocytes were also labeled with an anti-corneodesmosin antibody and visualized with scanning electron microscopy.

Results

We found a strong correlation between NMF levels and Dermal Texture Index scores in both acute and convalescent states (respective r = −0.80 and −0.75, P < .001 and P = .002). Most, but not all, VPs showed the presence of corneodesmosin abundantly all over the cell surface in homozygous/compound heterozygous FLG patients and, to a lesser extent, in heterozygous and wild-type patients.

Conclusions

NMF levels are highly correlated with corneocyte morphology in patients with AD. These corneocyte conformational changes shed further insight into the filaggrin-deficient phenotype and help explain the barrier defect in patients with AD with FLG LOF mutations.

El texto completo de este artículo está disponible en PDF.

Key words : Skin barrier, transepidermal water loss, atopic dermatitis, filaggrin, corneocyte

Abbreviations used : AD, AFM, CE, DTI, FLG, LOF, NMF, SC, SEM, TEWL, VP


Esquema


 Supported by the National Children's Research Centre Dublin, Ireland (to A.D.I and M.A.M.). The Centre for Dermatology and Genetic Medicine, University of Dundee, is supported by a Wellcome Trust Strategic Award (098439/Z/12/Z to W.H.I.M). The work performed by Serend-ip was supported by the German Ministry of Research grant no. 01DJ13022A (to C.R.).
 Disclosure of potential conflict of interest: C. Riethmuller holds a patent on analytic methods. M. A. McAleer has received research support from the National Children's Research Centre. L. E. Campbell, S. F. MacCallum, and W. H. I. McLean have received research support from the Wellcome Trust. A. D. Irvine has received research support from the National Children's Research Centre and has consultant arrangements with Regeneron. The rest of the authors declare that they have no relevant conflicts of interest.


© 2015  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 136 - N° 6

P. 1573 - décembre 2015 Regresar al número
Artículo precedente Artículo precedente
  • Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo-controlled crossover park study
  • Peter Kenney, Ole Hilberg, Anne Cathrine Laursen, Robert George Peel, Torben Sigsgaard
| Artículo siguiente Artículo siguiente
  • Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis
  • Tim Wiechers, Anja Rabenhorst, Tina Schick, Liane M. Preussner, Anja Förster, Peter Valent, Hans-Peter Horny, Karl Sotlar, Karin Hartmann

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.